Increased CD103−CD8+ TILs with TPEX phenotype replenish anti-tumor T cell pool in mismatch repair-proficient CRC
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04214-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jinsheng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, CD8-Positive T-Lymphocytes, DNA Mismatch Repair, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
While mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit strong immunogenicity and better response to immune checkpoint inhibitors, the more prevalent mismatch repair-proficient (pMMR) CRCs typically show poor T- cell infiltration and inferior outcomes. Profiling the limited tumor-infiltrating CD8 + T cells helps identify responders and guides new strategies to enhance their infiltration and function in pMMR CRC tumors. Our study reveals that the proportion and number of CD103 − CD8 + T (CD103N) cells are significantly increased in pMMR CRC tissue compared to adjacent non-tumor tissue. Distinguish from CD103 + CD8 + T (CD103P) cells with elevated T EX markers, these CD103N cells display a precursor exhausted T cells (T PEX ) phenotype with elevated stemness properties, reduced exhaustion markers, and retained functional capacity to secrete anti-tumor mediators. Moreover, CD103N cells in pMMR CRC shared a substantial number of identical TCR clonotypes with both CD103P cells in tumor and CD103N cell in peripheral blood. In dMMR CRC patients, enrichment of T PEX -like CD103N cells is associated with a favorable prognosis following anti-PD-1 therapy, suggesting their association with clinical outcome. Our findings identify an expanded population of CD103N cells exhibiting a T PEX phenotype with anti-tumor potential in pMMR CRC, highlighting their promise as therapeutic targets for recruitment into the tumor microenvironment to enhance the efficacy of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China.
- Department of Colorectal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, China.
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. wumi0704@126.com.
- Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, China. wumi0704@126.com.
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. wengxiufang@hust.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Zeng, J., Zhou, T., Wu, M., & Weng, X. (2025). Increased CD103−CD8+ TILs with TPEX phenotype replenish anti-tumor T cell pool in mismatch repair-proficient CRC. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04214-w
Vancouver
Liu J, Zeng J, Zhou T, Wu M, Weng X. Increased CD103−CD8+ TILs with TPEX phenotype replenish anti-tumor T cell pool in mismatch repair-proficient CRC. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04214-w
BibTeX
@article{Liu2025,
author = {Liu, Jinsheng and Zeng, Jintao and Zhou, Ting and Wu, Mi and Weng, Xiufang},
title = {Increased CD103−CD8+ TILs with TPEX phenotype replenish anti-tumor T cell pool in mismatch repair-proficient CRC},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04214-w}
}
EUVIMED